These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10579836)

  • 21. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
    He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M
    Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.
    Wonacott A; Cooke R; Hayes FR; Hann MM; Jhoti H; McMeekin P; Mistry A; Murray-Rust P; Singh OM; Weir MP
    J Med Chem; 1993 Oct; 36(21):3113-9. PubMed ID: 8230097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization.
    Flausino OA; Dufau L; Regasini LO; Petrônio MS; Silva DH; Rose T; Bolzani VS; Reboud-Ravaux M
    Curr Med Chem; 2012; 19(26):4534-40. PubMed ID: 22963666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
    Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
    Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of novel inhibitors of the HIV-1 protease: difunctional enols of simple N-protected amino acids.
    Vaillancourt M; Vanasse B; Le Berre N; Cohen E; Sauvé G
    Bioorg Med Chem; 1994 May; 2(5):343-55. PubMed ID: 7922146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease.
    Cígler P; Kozísek M; Rezácová P; Brynda J; Otwinowski Z; Pokorná J; Plesek J; Grüner B; Dolecková-Maresová L; Mása M; Sedlácek J; Bodem J; Kräusslich HG; Král V; Konvalinka J
    Proc Natl Acad Sci U S A; 2005 Oct; 102(43):15394-9. PubMed ID: 16227435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
    Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P
    J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
    J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
    Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.
    Coburger C; Wollmann J; Krug M; Baumert C; Seifert M; Molnár J; Lage H; Hilgeroth A
    Bioorg Med Chem; 2010 Jul; 18(14):4983-90. PubMed ID: 20598550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
    Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
    Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
    Zhao C; Sham HL; Sun M; Stoll VS; Stewart KD; Lin S; Mo H; Vasavanonda S; Saldivar A; Park C; McDonald EJ; Marsh KC; Klein LL; Kempf DJ; Norbeck DW
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5499-503. PubMed ID: 16203141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
    J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
    Wannberg J; Kaiser NF; Vrang L; Samuelsson B; Larhed M; Hallberg A
    J Comb Chem; 2005; 7(4):611-7. PubMed ID: 16004505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.